Actively Recruiting
Safety Monitoring of Efluelda Vaccine in Adults 65 Years and Older in Korea Under Routine Care
Led by Sanofi · Updated on 2026-10-20
670
Participants Needed
15
Research Sites
3 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety of Efluelda, a high-dose trivalent influenza vaccine, in adults aged 65 years or older under routine clinical practice in the Republic of Korea. This observational, open-label, multi-center active safety surveillance study aims to monitor the occurrence of adverse events and adverse drug reactions in this population following vaccination. The study complies with local risk management regulations to ensure thorough monitoring. Participants will receive one intramuscular dose of Efluelda on Day 1. The study does not involve any comparison groups or placebo and is conducted in a standard healthcare setting. The participation duration is approximately 28 to 35 days, which may be extended to 36 to 42 days if the second visit is not completed on time. During the study, participants will be monitored for various reactions, including solicited injection site reactions and systemic reactions within 7 days after vaccination. Unsolicited adverse events, adverse drug reactions, serious adverse events, and adverse events of special interest will be tracked from vaccination until the last participant contact, up to about 42 days. This monitoring helps researchers understand the vaccines safety profile in older adults over the short term.
CONDITIONS
Brief Title
Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here